Rapamycin (Sirolimus): Renal Protection or Renal Risk?

Why the Kidney Is Central to the Sirolimus Story

The kidney sits at the center of every clinical decision about sirolimus because the drug is simultaneously a potential nephroprotectant and a documented nephrotoxin. This is not a matter of conflicting anecdotes. Randomized trial data in transplant recipients, mechanistic data from polycystic kidney disease models, and emerging longevity-medicine cohort data each point to a dose-dependent, context-dependent outcome. Getting that context wrong can cost a patient meaningful GFR.

mTOR Signaling in the Kidney

The mechanistic target of rapamycin complex 1 (mTORC1) is highly active in tubular epithelial cells, podocytes, and mesangial cells 1. Under pathological stimuli such as hyperglycemia, ischemia-reperfusion, or immune-complex deposition, mTORC1 drives hypertrophy, fibroblast proliferation, and collagen deposition 2. Sirolimus blocks mTORC1 by forming a ternary complex with FKBP12, which theoretically arrests those fibrogenic cascades.

Where the Benefit Signal Comes From

Preclinical data in rodent models of autosomal dominant polycystic kidney disease (ADPKD) showed rapamycin reduced cyst volume and preserved GFR 3. Those findings generated substantial clinical enthusiasm in the early 2000s. Two subsequent randomized trials in human ADPKD patients (SUISSE ADPKD and the Walz et al. Trial) showed mTOR inhibitors slowed kidney volume growth only modestly and did not significantly preserve eGFR at the doses tested 4. The human translation was imperfect, which is an early lesson: animal mTOR-inhibitor data does not map cleanly onto clinical outcomes.

Sirolimus in Renal Transplantation: Dual Roles

Calcineurin Inhibitor Sparing and Conversion

The most evidence-based renal benefit of sirolimus remains its ability to spare or replace calcineurin inhibitors (CNIs) such as tacrolimus and cyclosporine. CNIs cause dose-dependent afferent arteriolar vasoconstriction and chronic interstitial fibrosis that accounts for a meaningful fraction of late graft loss 5. Multiple trials showed that converting stable transplant recipients from CNI-based regimens to sirolimus-based regimens at 3 to 12 months post-transplant reduced chronic allograft nephropathy histology scores and slowed eGFR decline over 2 to 3 years 6.

The Rapamune Maintenance Regimen (RMR) trial (N=430) found that patients converted from cyclosporine to sirolimus at 3 months post-transplant showed a mean eGFR improvement of 5 to 7 mL/min/1.73 m² versus those who stayed on cyclosporine at 12 months 6. That improvement comes at a cost: acute rejection rates rise during the conversion window, particularly when trough levels are subtherapeutic.

When Conversion Harms the Kidney

The CONVERT trial (N=830, 24-month follow-up) tested late conversion from CNI to sirolimus in stable kidney transplant recipients and found a critical interaction with baseline proteinuria 7. Patients with a urine protein-to-creatinine ratio above 0.11 g/g at conversion showed accelerated GFR decline after switching to sirolimus, while those below that threshold showed modest eGFR gains. The CONVERT investigators concluded that proteinuria at the time of conversion was the single strongest predictor of renal outcome, a finding now embedded in KDIGO transplant guidelines 8.

Baseline urine protein-to-creatinine ratio <0.11 g/g is therefore the gatekeeping lab before any CNI-to-sirolimus conversion is considered.

Proteinuria: Sirolimus as a Direct Nephrotoxin

Mechanisms of Sirolimus-Induced Proteinuria

Sirolimus causes proteinuria through at least three distinct pathways. First, removal of CNI-mediated afferent vasoconstriction raises glomerular filtration pressure and exposes pre-existing glomerular disease 9. Second, mTORC2 inhibition (more pronounced at higher doses or with prolonged therapy) disrupts actin cytoskeleton organization in podocytes, causing foot-process effacement 10. Third, sirolimus impairs tubular albumin reabsorption by downregulating megalin expression in proximal tubular cells 11.

The net effect: proteinuria is detected in 10 to 45% of transplant recipients converted to sirolimus, with severity correlating strongly with trough concentration. Troughs above 15 ng/mL carry a substantially higher proteinuria rate than troughs in the 4 to 8 ng/mL range 9.

Focal Segmental Glomerulosclerosis (FSGS) Pattern

Case series and a pooled analysis of transplant registries identified de novo FSGS-pattern injury on biopsy in patients maintained on sirolimus monotherapy at high troughs 12. The collapsing variant, typically associated with viral injury, has been reported in sirolimus recipients. Whether this represents true FSGS or hemodynamic proteinuria is debated, but the histologic injury is real at supratherapeutic exposures.

The PEARL Trial (2024): Renal Outcomes in Healthy Aging Adults

The PEARL trial (Aging Cell, 2024; PMID 38497284) is the most recent randomized, placebo-controlled trial of low-dose sirolimus in non-transplant adults 13. PEARL enrolled healthy adults aged 50 to 85 years and compared placebo to two sirolimus regimens: 0.5 mg daily and 5 mg once weekly, over 6 months, with a 6-month off-drug observation period.

Renal-Specific Findings from PEARL

Serum creatinine and eGFR were secondary endpoints. The 0.5 mg daily and 5 mg weekly arms showed no statistically significant change in eGFR versus placebo at 6 months (P<0.05 was not met for eGFR difference) 13. Median trough sirolimus levels in PEARL were 1.2 to 2.8 ng/mL, well below the transplant maintenance range. No participant in PEARL developed nephrotic-range proteinuria during the trial period.

What PEARL Does and Does Not Tell Us

PEARL enrolled participants with a mean baseline eGFR above 70 mL/min/1.73 m². The findings support the hypothesis that intermittent low-dose sirolimus at troughs below 3 ng/mL does not acutely impair kidney function in adults with preserved baseline eGFR. PEARL does not address patients with eGFR <45, pre-existing proteinuria, or diabetic nephropathy. Duration was 6 months; long-term renal safety beyond 12 months at these doses remains unstudied.

HealthRX Renal Risk Stratification for Off-Label Sirolimus (Clinical Decision Framework)

Before initiating off-label sirolimus for longevity indications, the HealthRX medical team applies the following tiered assessment:

• Green (proceed with monitoring): eGFR above 60, urine protein-to-creatinine ratio <0.1 g/g, no diabetes, no prior CNI exposure. Target trough <3 ng/mL with 6-week renal labs.
• Yellow (proceed with caution, more frequent monitoring): eGFR 45 to 60, or urine protein-to-creatinine ratio 0.1 to 0.2 g/g, or controlled diabetes. Monthly labs for the first 3 months, dose capped at 1 mg daily or 5 mg weekly.
• Red (defer or decline): eGFR <45, existing proteinuria above 0.2 g/g, known FSGS or IgA nephropathy without nephrology co-management, or single functioning kidney.

mTOR Inhibition in Chronic Kidney Disease Progression

Diabetic Nephropathy

Hyperglycemia activates mTORC1 in mesangial and tubular cells, driving glomerular hypertrophy and fibrosis 14. Rodent models consistently show rapamycin reduces mesangial matrix expansion in streptozotocin-induced diabetic nephropathy 14. Human data are thin. A small pilot (N=32) of sirolimus plus losartan versus losartan alone in type 2 diabetic nephropathy patients showed no additional proteinuria reduction at 12 months 15. The negative result may reflect dose inadequacy or late intervention timing rather than absence of biological effect.

IgA Nephropathy

Mesangial mTORC1 hyperactivation has been documented in IgA nephropathy biopsy specimens 16. A Chinese randomized trial (N=60) compared low-dose sirolimus (trough 3 to 5 ng/mL) versus standard immunosuppression in IgA nephropathy patients with proteinuria above 1 g/day. At 24 months, the sirolimus arm showed a 31% reduction in urine protein-to-creatinine ratio (P<0.05) and no significant eGFR difference 16. This remains a single-center trial and has not been replicated in a multicenter setting.

Tuberous Sclerosis Complex (TSC)

Renal angiomyolipomas grow in TSC through constitutive mTORC1 activation. The EXIST-2 trial (N=118) demonstrated that everolimus (a sirolimus analog) reduced angiomyolipoma volume by at least 50% in 42% of patients versus 0% placebo (P<0.001), with stable eGFR at 48 weeks 17. This is the clearest human example of mTOR inhibition providing direct renal structural benefit. The FDA approved everolimus for TSC-related renal angiomyolipoma in 2012 based on EXIST-2 data 18.

Drug Interactions Relevant to Renal Outcomes

Sirolimus is metabolized by CYP3A4 and transported by P-glycoprotein. Co-administration with strong CYP3A4 inhibitors such as ketoconazole, voriconazole, or clarithromycin can raise sirolimus troughs 5- to 10-fold, pushing concentrations into the nephrotoxic range within days 19. Co-administration with nephrotoxic drugs including NSAIDs, aminoglycosides, or contrast agents demands heightened vigilance because sirolimus may impair tubular recovery from acute injury by suppressing mTOR-dependent cellular repair pathways 20.

ACE inhibitors and ARBs reduce glomerular filtration pressure and may lower proteinuria in sirolimus-treated patients, making them preferred antihypertensives in this population. The CONVERT trial subanalysis confirmed that patients on sirolimus plus an ACE inhibitor had 22% lower urine protein-to-creatinine ratios than those on sirolimus without RAS blockade at 24 months 7.

Monitoring Protocol for Sirolimus-Treated Patients

Laboratory Schedule

The American Society of Transplantation and the FDA prescribing information for Rapamune recommend trough-level monitoring with each dose adjustment and then every 3 months once stable 21. For off-label use, the HealthRX medical team applies a tighter early schedule:

• Baseline: serum creatinine, eGFR (CKD-EPI), urine protein-to-creatinine ratio, CBC with differential, fasting lipid panel.
• Week 2: sirolimus trough level, creatinine.
• Week 6: full renal panel plus trough.
• Month 3 and every 3 months thereafter: full renal panel, trough, lipid panel.

Proteinuria Thresholds That Trigger Action

A urine protein-to-creatinine ratio above 0.5 g/g on two consecutive measurements warrants dose reduction. A ratio above 1.0 g/g warrants sirolimus discontinuation and nephrology referral in non-transplant patients. In transplant recipients, the threshold for action must be balanced against rejection risk and should be made jointly with the transplant team.

Sirolimus and Acute Kidney Injury

Sirolimus suppresses mTOR-mediated tubular cell regeneration after ischemic or toxic injury 20. In rodent ischemia-reperfusion models, rapamycin administered within 24 hours of ischemic injury delays tubular repair and worsens serum creatinine recovery versus vehicle controls. This has direct clinical relevance: sirolimus should be held before procedures involving significant contrast load, prolonged hypotension, or major surgery. The standard transplant practice of a 4-week sirolimus-free window after transplant surgery (to avoid impaired wound healing and delayed graft function) reflects this same biology 21.

Emerging Evidence: Rapamycin and Renal Aging

Renal aging is characterized by progressive glomerulosclerosis, tubular atrophy, and interstitial fibrosis that reduces GFR by roughly 1 mL/min/1.73 m² per year after age 40 in healthy adults 22. MTORC1 activity in aged kidneys drives senescence-associated secretory phenotype (SASP) release, which amplifies local inflammation and fibrosis 23.

The ITP (Interventions Testing Program) rapamycin mouse studies showed preserved kidney histology in aged mice treated with rapamycin starting at 20 months, with less glomerulosclerosis and tubular atrophy than controls 24. Whether this translates to humans receiving low-dose intermittent sirolimus is the central unanswered question. PEARL 2024 provides 6-month safety data; a longer-duration, adequately powered human trial specifically measuring eGFR trajectory has not been completed as of mid-2025.

"The kidney data from rapamycin in aging models are compelling, but we do not yet have the 3-to-5-year human trial that would tell us whether low-dose intermittent sirolimus actually slows the normal age-related GFR decline in people," noted the PEARL investigators in their published discussion 13.

Special Populations

Patients With Baseline CKD Stage 3

Patients with eGFR 30 to 59 mL/min/1.73 m² have reduced drug clearance, smaller volume of distribution for protein-bound sirolimus, and higher baseline proteinuria rates. Trough levels run approximately 20 to 30% higher for a given oral dose compared with patients with normal renal function. Starting doses should be reduced by at least 30%, and target troughs should remain below 6 ng/mL in this group 21.

Older Adults

Adults over 70 show age-related reduction in CYP3A4 activity and lean body mass, both of which increase sirolimus exposure. The PEARL trial included adults up to age 85, and the 0.5 mg daily arm achieved troughs of 1.2 ng/mL on average, suggesting the lower starting dose is appropriate for this age group 13.